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Abstract: The commercial production of therapeutic or diagnostic proteins in recombinant micro-
organisms is of considerable interest. Several microbial protein production systems have been developed. So 
far, Escherichia coli have been the commonly employed host. However, proteins expressed in this host remain 
intracellular and often precipitate as inclusion bodies, which may seriously complicate downstream-
processing. Faced with this problem, several genera of Gram-positive bacteria are being tested as host for the 
production of heterologous proteins due to their ability to efficiently secrete proteins in the culture medium. 
Among them is the genus Streptomyces since several of its species are known to secrete high amounts of 
proteins. Due to the absence of an extensive restriction-modification system, limited protease activity and the 
availability of suitable vector systems, Streptomyces lividans is the host of choice for the secretory production of 
heterologous proteins. The presented results show, that S. lividans can act as an interesting host to produce a 
number of proteins useful in several disease areas important in the worldwide pharmaceutical sales: i.e. 
oncology, immunology, cardiovascular diseases and infectious diseases. 
      Journal of Business Chemistry Vallin et al. September 2005 
 
 
© 2005 Institute of Business Administration                                 108  ISSN 1613-9615  
 www.businesschemistry.org 
Introduction 
Streptomyces 
Streptomycetes are Gram-positive soil 
microorganisms that produce a wide variety of 
secondary metabolites, many of which have potent 
biological activities. They produce more than half 
of the known biologically active microbial 
products, including many commercially important 
antibiotics, immunosuppressive compounds, 
animal health products, and agrochemicals [1,2,3]. 
They also produce various enzymes that are 
commercially and academically valuable as 
extracellular enzymes capable of degrading 
lignocellulosics [4,5]. This vast reservoir of diverse 
products makes Streptomyces one of the most 
important industrial microbial genera and 
consequently, a battery of tools for genetic 
manipulation of this germs is available [6].  
Streptomyces coelicolor A(3)2 is genetically the best 
characterised Streptomyces strain. However, over the 
past years, Streptomyces lividans 66 or its derivatives 
were evaluated as potential host for heterologous 
protein production [7,8,9]. Secretory production of 
heterologous proteins by-passes the problem of 
inclusion body formation in the cytoplasm a 
problem encountered in the commonly used E. coli 
system. Additional advantages of S. lividans include 
very efficient secretion directly into the growth 
medium, the absence of lipopolysaccharides and 
simple genetic manipulation, and low-protease 
activity. Streptomyces lividans has been used for the 
heterologous secretion of several polypeptides of 
bacterial and eukaryotic origin. In most cases, 
heterologous genes are fused to signal sequences 
from highly expressed/secreted proteins [10].  
Recombinants proteins production 
The production of recombinant proteins by 
microbial fermentation is a main research topic in 
many bio-industries [11,12]. The Production of 
therapeutic proteins will increase 15% annually the 
next 5 years  Examples: The  worldwide sales for 
therapeutics IFN a (+PEGylated)  will be aprox. 
$2700 million as Antitumor/Anti-HIV [13]. 
 
For a variety of biological and technical 
reasons, proteins of therapeutic or commercial 
interest are synthesized in either eukaryotic or 
prokaryotic systems. The most extensively used 
prokaryotic system  Escherichia coli, offers several 
advantages including  growth on inexpensive 
carbon sources, rapid biomass accumulation, 
amenability to high cell-density fermentations and 
simple process scale-up. But problems with 
inclusion body formation, rapid heterologous 
protein degradation and the need to purify the 
protein of interest free of endogenous protein 
often makes downstream-processing very labor-
intensive and thus expensive. These drawbacks 
drive to search for alternative production systems. 
As a consequence, a variety of expression 
platforms has been described ranging from Gram-
negative and Gram-positive prokaryotes, over 
several yeasts and filamentous fungi to mammalian 
cells [14,15,16,17]. 
In this study we investigated showed the 
feasibility of Streptomyces lividans as a host for the 
expression/secretion of the therapeutic proteins, 
human interferon alpha 2b (HuIFNa-2b). 
Huifna2b cDNA was fused to signal sequences of 
well-expressed native genes. Under appropriate 
fermentation conditions, significant amounts of 
mature biologically active HuIFNa-2b could be 
recovered from the spent growth media. 
Materials and Methods  
For expression studies, S. lividans derivatives 
were cultured in a suitable liquid medium (10% 
sucrose, 1% yeast extract, 1% glucose, 0.5% NaCl, 
0.5% soya fluor, 1.7% triptone, 0.25% K2HPO4) at 
27ºC and 300 rpm.  
 
HuIFNa-2b from culture supernatants of S. 
lividans transformed with pADXS, pUCIAS, 
pOVsiIFN or pOW15 was detected by 
immunoblot and ELISA according to Sánchez et 
al. (1998) [18]. 
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Results and Discussion 
Secretion of human interferon alpha 2b 
(HuIFNa–2b) by Streptomyces lividans 
The interferons are a multigene family with a 
broad range of biological properties, including 
potent antiviral, antiproliferative and 
immunomodulatory activities. 
The cloning the huifna2b cDNA was achieved 
through recombinant DNA technology [17]. The 
large-scale production of this protein for 
therapeutic purposes using E. coli was achieved 
several years ago but the overexpression of 
HuIFNa-2b in E. coli leaded to the formation of 
inclusion bodies. In this study, S. lividans was used 
as an alternative host for the obtainment of 
HuIFNa-2b. Therefore the cDNA was placed 
under control of the regulatory sequences i.e. 
promoter, Shine-Dalgarno and signal sequence of 
Streptomyces venezuelae subtilisin inhibitor (vsi) gene  
 
or Streptomyces exfoliatus M11 Lipase A (lipA) gene. 
The results of the immunoblot analysis of secreted 
HuIFN a-2b are shown in the fig.1. The ELISA 
results and obtained antiviral titers of HuIFNa-2b 
secreted by recombinant strains of S. lividans are 
shown in table 1.  
Plasmid pADXS encodes a fusion protein LipA-
sp/HuIFNa–2b maintaining nine additional 
amino acid residues of mature LipA between the 
LipA signal peptide and HuIFNa–2b. [pUCIAS] 
encodes a fusion protein LipA-sp/HuIFNa–2b 
with three additional amino acid residues of 
mature LipA at the border of the fusion 
pOVsiIFN encodes a fusion protein Vsi-
sp/huIFNa–2b containing two amino acid 
residues of mature Vsi between the  Vsi signal 
peptide and HuIFNa–2b.   
The protein HuIFNa–2b was thus expressed in 
S. lividans and subsequently secreted into the 
medium. The yield obtained for this protein and 
their biology activity results demonstrated the 
potential of S. lividans as an alternative host for 
E.coli aiming the production of HuIFNa-2b. 
 
 
Sample mg/L IU/L 
S. lividans 
TK24 [pADXS] 
0.58197 9.4 x 107 
S. lividans 
TK24 [pUCIAS] 
0.22566 1.8 x 107 
S. lividans 
TK24 [pOVsiIFN] 
0.23590 0.9 x107 
 
 
 
 
 
Table 1: ELISA results and Antiviral titers of S. lividans TK 24 recombinants (Interferon-induced 
antiviral activity was determined by the inhibition of the cytopathic effect of mengovirus on Hep-2 
cells)  
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Figure 1: Immunoblot analysis of secreted HuIFN a-2b. Lanes: 
1 20µl S. lividans TK24 [pOW15] culture supernatant 
2 Prestained SDS-PAGE standard, Bio-Rad, Carbonic anhydrase 38.289 kDa, Soybean  
trypsin inhibitor 29.678 kDa, Lysozyme 20.669 kDa, Aprotinin 6.969 kDa                  
3 20µl S. lividans TK24 [pADXS] culture supernatant 
4 20µl S. lividans TK24 [pUCIAS] culture supernatant 
5 20µl S. lividans TK24 [pOVsiIFN] culture supernatant 
6 25 ng of reference HuIFN a
Conclusions 
The presented results show, that S. lividans can 
act as an interesting host to produce a number of 
proteins useful in several disease areas important 
in the worldwide pharmaceutical sales: i.e. 
oncology, immunology, cardiovascular diseases 
and infectious diseases through a cost effective 
production systems. Although proteins of 
prokaryotic origin are in general more efficiently 
produced than eukaryotic proteins in Streptomyces 
lividan. Yields can be optimized using strong 
promoters and efficient translation signals of well-
expressed native genes. Furthermore translocation 
signals can be modified in order to improve 
heterologous protein production [14]. As such for 
each biopharmaceutical protein a tailor-made 
secretion strain can be constructed.  
 
 
Future developments of the fermentation 
processes will be investigated in order to evaluate 
the industrial applicability of the engineered strains  
and downstream processing will be optimized 
allowing the most efficient recovery of the 
secreted proteins from the culture broth. 
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